Flag of the European Union EU Clinical Trials Register Help

Clinical trials for alpha-

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44349   clinical trials with a EudraCT protocol, of which   7376   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,091 result(s) found for: alpha-. Displaying page 44 of 55.
    «« First « Previous 40  41  42  43  44  45  46  47  48  Next» Last»»
    EudraCT Number: 2013-002645-11 Sponsor Protocol Number: SPP1C302 Start Date*: 2013-12-04
    Sponsor Name:SBI Pharmaceuticals Co., Ltd.
    Full Title: An Open-label, Randomized Study to Evaluate Safety, Tolerability and Pharmacokinetics of 5-ALA/SFC in Cancer Patients with Solid Tumors with Chemotherapy Induced Anemia.
    Medical condition: Cancer Patients with Solid Tumors with Chemotherapy Induced Anemia
    Disease: Version SOC Term Classification Code Term Level
    16.1 10005329 - Blood and lymphatic system disorders 10002034 Anaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2018-001650-98 Sponsor Protocol Number: AC1802 Start Date*: 2018-12-10
    Sponsor Name:University of Edinburgh and NHS Lothian [...]
    1. University of Edinburgh and NHS Lothian
    2. NHS Lothian
    Full Title: Alpha 2 agonists for sedation to produce better outcomes from critical illness (A2B Trial): A randomised, parallel-group, allocation concealed, controlled, open, phase 3 pragmatic clinical and cost...
    Medical condition: Any patient requiring intensive care treatment due to critical illness.
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10033305 Oversedation LLT
    20.0 10029205 - Nervous system disorders 10039897 Sedation PT
    21.1 100000004865 10049124 Sedation during medical procedure LLT
    20.1 10029205 - Nervous system disorders 10039898 Sedation excessive LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2013-001185-41 Sponsor Protocol Number: POINT Start Date*: 2013-11-26
    Sponsor Name:University of California San Francisco Stroke Sciences Group
    Full Title: Platelet-Oriented Inhibition in New TIA and minor ischemic stroke (POINT) Trial, a randomized, double blind, multicentre clinical trial
    Medical condition: Transient Ischemic Attack and Minor Stroke
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10068644 Brain stem stroke PT
    14.1 10029205 - Nervous system disorders 10044390 Transient ischaemic attack PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) ES (Completed) DE (Prematurely Ended) FI (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-001989-38 Sponsor Protocol Number: IMCRELA Start Date*: 2021-07-08
    Sponsor Name:Facultad de medicina y ciencias de la salud de la Universidad Católica de Valencia
    Full Title: IMPACT OF THE COMBINED TREATMENT OF THE LIPOSOMATED POLYPHENOLS CÚRCULA AND RESVERATROL® WITH DUTASTERIDE, IN THE CLINICAL IMPROVEMENT OF PATIENTS WITH ALS TREATED WITH RILUZOLE
    Medical condition: Amyotrophic Lateral Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-002093-20 Sponsor Protocol Number: H9H-MC-JBEF Start Date*: 2017-03-16
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 1b/2 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of a Novel Transforming Growth Factor-beta Receptor I Kinase Inhibitor (Galunisertib) Administered i...
    Medical condition: Advanced Refractory Solid Tumours (Phase 1b) and in Recurrent or Refractory Non–Small Cell Lung Cancer or Hepatocellular Carcinoma, (Phase 2)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-004632-38 Sponsor Protocol Number: GCTSK005 Start Date*: 2017-11-09
    Sponsor Name:Národný onkologický ústav
    Full Title: Phase II study of Avelumab in multiple relapsed/refractory testicular germ cell cancer.
    Medical condition: Extracranial primary germ cell cancer, seminoma, or nonseminoma.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061378 Testicular germ cell cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10039956 Seminoma PT
    20.0 100000021189 10029557 Non-seminoma testicular cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SK (Completed)
    Trial results: View results
    EudraCT Number: 2021-003469-36 Sponsor Protocol Number: THEA_HLF_1/21 Start Date*: 2021-09-17
    Sponsor Name:Laboratorios Théa, S.A.
    Full Title: “Prospective evaluation of the efficacy and safety of topical hydrocortisone treatment on clinical signs and symptoms of dry eye disease associated with moderate meibomian gland dysfunction”
    Medical condition: Dry Eye (DE) and Meibomian gland dysfunction (MGD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10015919 - Eye disorders 10013774 Dry eye PT
    20.1 10015919 - Eye disorders 10065062 Meibomian gland dysfunction PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-006604-11 Sponsor Protocol Number: NV19865 Start Date*: 2007-12-06
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A Phase II, Randomized, Double-Blinded, Multicenter, Dose Finding Study Evaluating the Efficacy and Safety of the HCV Polymerase Inhibitor Prodrug (RO4588161) when given in combination with Pegasys...
    Medical condition: Chronic hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008912 Chronic hepatitis C LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) FR (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-011003-23 Sponsor Protocol Number: GFT505-209-4 Start Date*: 2009-05-28
    Sponsor Name:GENFIT
    Full Title: A Pilot study to evaluate the Efficacy and Safety of GFT505 (80mg) orally administered once daily for 35 days in patients presenting with impaired glucose tolerance and abdominal obesity. A double ...
    Medical condition: patients presenting with impaired glucose tolerance and abdominal obesity
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036481 Pre-diabetes LLT
    9.1 10059179 Abdominal obesity LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2010-020452-64 Sponsor Protocol Number: version2.0 Start Date*: 2010-10-05
    Sponsor Name:Hull and East Yorkshire Hospitals NHS Trust
    Full Title: A prospective randomisd open label study to determine the effects of intravenous iron administration on markers of acute kidney injury in chronic kidney disease (CKD)
    Medical condition: patients with known chonic kidney disease with functional or absolute Iron deficiency Anaemia, and are greater than 18 years will be given repleacement iron therapy accoring to current local protoc...
    Disease: Version SOC Term Classification Code Term Level
    15.0 10005329 - Blood and lymphatic system disorders 10022973 Iron deficiency anaemias LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-002225-10 Sponsor Protocol Number: EMPA-HEART Start Date*: 2016-09-28
    Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
    Full Title: Impact of empagliflozin on left ventricular functions: a single center, phase III, randomized, open-label, active treatment-controlled, parallel study in patients with type 2 diabetes and normal le...
    Medical condition: type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    21.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-015121-37 Sponsor Protocol Number: ANRS HC 23 Start Date*: 2009-12-10
    Sponsor Name:ANRS
    Full Title: Etude multicentrique randomisée ouverte comparant la réduction virale et la tolérance de l’association IFN alpha-2b XL + ribavirine versus IFN peg alpha-2b + ribavirine chez des patients atteints d...
    Medical condition: Evaluation de l’activité antivirale d’injections hebdomadaires d’un nouvel interféron α-2b à libération prolongée formulé avec Medusa® (IFNα-2bXL) chez des patients atteints d’hépatite chronique v...
    Disease: Version SOC Term Classification Code Term Level
    12.0 10008912 Chronic hepatitis C LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2008-000859-10 Sponsor Protocol Number: ANRS HC 20 Start Date*: 2009-04-10
    Sponsor Name:ANRS
    Full Title: Etude pilote, multicentrique, évaluant l’efficacité d’un traitement anti VHC optimisé (induction par 360µg/S de PegIFN-alpha 2a + 18mg/kg/j de RBV pendant 6 mois puis en fonction de la réponse viro...
    Medical condition: Cet essai vise à étudier la réponse à un re-traitement optimisé de l’hépatite C chez des patients co-infectés VIH-VHC (génotype 1 et 4), non répondeurs aux premiers traitements pour le VHC.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008912 Chronic hepatitis C LLT
    9.1 10001509 AIDS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2013-004974-82 Sponsor Protocol Number: 2013.837 Start Date*: 2014-04-04
    Sponsor Name:Hospices Civils de Lyon
    Full Title: PETALS study : PEgylated interferon-alpha2a and TAsigna® for first Line therapy of Philadelphia chromosome-positive chronic phase CML patientS
    Medical condition: Chronic phase chronic myeloid leukaemia with Philadelphia chromosome positive or BCR-ABL positive
    Disease: Version SOC Term Classification Code Term Level
    19.1 10022891 - Investigations 10034877 Philadelphia chromosome positive PT
    19.1 100000004864 10052065 Chronic phase chronic myeloid leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-003736-77 Sponsor Protocol Number: E7080-A001-216 Start Date*: 2023-03-28
    Sponsor Name:Eisai Inc.
    Full Title: A Phase 1/2 Study of Lenvatinib in Combination with Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
    Medical condition: Recurrent and Refractory Solid Tumors
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2022-001398-30 Sponsor Protocol Number: MEDOPP437 Start Date*: 2023-05-08
    Sponsor Name:Medica Scientia Innovation Research, S.L.
    Full Title: PHASE II STUDY FOR PIK3CA/PTEN-ALTERED ADVANCED METAPLASTIC BREAST CANCER TREATED WITH MEN1611 MONOTHERAPY OR IN COMBINATION WITH ERIBULIN -THE SABINA STUDY- English PHASE II STUDY WITH MEN1611 M...
    Medical condition: Hormone Receptor (HR)-known/ Human Epidermial Growth Factor Receptor 2 (HER2)-negative, phosphatidylinositol-4,5-bisphosphate 3kinase catalytic subunit alpha (PIK3CA)/ Phosphatase and Tensin Homolo...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-002352-36 Sponsor Protocol Number: BO41929 Start Date*: 2022-05-02
    Sponsor Name:F. Hoffmann La Roche Ltd.
    Full Title: A PHASE II, OPEN-LABEL, SINGLE-ARM DECENTRALIZED HOME-BASED APPROACH STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ALECTINIB IN LOCALLY ADVANCED OR METASTATIC ALK-POSITIVE SOLID TUMORS
    Medical condition: Anaplastic lymphoma kinase (ALK)-positive solid tumors
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004864 10084713 Tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2020-000472-37 Sponsor Protocol Number: NN1436-4479 Start Date*: 2020-12-17
    Sponsor Name:Novo Nordisk A/S
    Full Title: A 26-week double blinded, multiregional, trial comparing the effect and safety of once weekly insulin icodec and once daily insulin degludec 100 units/mL, both in combination with non-insulin anti-...
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) AT (Completed) DK (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2019-000610-10 Sponsor Protocol Number: RivAsA Start Date*: 2020-01-27
    Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE
    Full Title: Effects of low-dose Rivaroxaban combined with low-dose Aspirin versus low-dose aspirin alone on in vivo platelet Activation, endothelial function and inflammation in type 2 diabetic patients with s...
    Medical condition: type 2 diabetic patients with stable peripheral or carotid artery disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004866 10067825 Peripheral arterial disease LLT
    21.0 10027433 - Metabolism and nutrition disorders 10053247 Insulin-requiring type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001547-12 Sponsor Protocol Number: DC2017RACELINES01 Start Date*: 2017-12-21
    Sponsor Name:VU University Medical Center
    Full Title: A phase 4, monocenter, randomized, double-blind, comparator-controlled, 3-armed parallel mechanistic intervention trial to assess the effect of 8-week empagliflozin (SGLT-2 inhibitor) monotherapy, ...
    Medical condition: Type 2 Diabetes Mellitus
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 40  41  42  43  44  45  46  47  48  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jul 16 09:45:25 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA